^
    Back
    Association details:
    Biomarker:CARD11 mutation
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Am J Transl Res
    Title:

    CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade

    Published date:
    01/15/2021
    Excerpt:
    CARD11 mutation is associated with longer OS and a better prognosis after ICI treatment. Therefore, the CARD11 gene can be used as a biomarker for predicting the efficacy of ICIs in SKCM patients.